AstraZeneca PLC (NASDAQ:AZN) shares, rose in value on Thursday, July 22, with the stock price up by 0.55% to the previous day’s close as strong demand from buyers drove the stock to $58.09.
Actively observing the price movement in the recent trading, the stock is buoying the session at $57.77, falling within a range of $57.53 and $58.055. The value of beta (5-year monthly) is 0.21 whereas the PE ratio is 38.21 over 12-month period. Referring to stock’s 52-week performance, its high was $60.93, and the low was $46.48. On the whole, AZN has fluctuated by -0.93% over the past month.
The company’s Forward Dividend Ratio is 1.40, with its dividend yield at 2.42%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.48, which is expected to increase to $0.57 for fiscal year $3.32 and then to about $4.17 by fiscal year 2022. Data indicates that the EPS growth is expected to be 65.20% in 2022, while the next year’s EPS growth is forecast to be 25.60%.
Analysts have estimated the company’s revenue for the quarter at $7.34 billion, with a low estimate of $7.19 billion and a high estimate of $7.61 billion. According to the average forecast, sales growth in current quarter could jump up 17.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $31.52 billion, representing an increase of 18.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that AZN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
26 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 3 analyst(s), 20 recommend it as a Buy and 2 called the AZN stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 1 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 2.01, with the price of AZN currently trading nearly -1.71% and 0.48% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.20, while the 7-day volatility ratio is showing 1.99% which for the 30-day chart, stands at 1.35%. Furthermore, AstraZeneca PLC (AZN)’s beta value is 0.55, and its average true range (ATR) is 0.96. The company’s stock has been forecasted to trade at an average price of $65.82 over the course of the next 52 weeks, with a low of $47.99 and a high of $75.03. Based on these price targets, the low is 17.39% off current price, whereas the price has to move -29.16% to reach the yearly target high. Additionally, analysts’ median price of $66.02 is likely to be welcomed by investors because it represents a decrease of -13.65% from the current levels.
A comparison of AstraZeneca PLC (AZN) with its peers suggests the former has fared considerably weaker in the market. AZN showed an intraday change of 0.55% in today’s session so far, and over the past year, it shrunk by -0.52%%. In comparison, Eli Lilly and Company (LLY) has moved higher at 0.70% today and is up 43.55% over the past 12 months. On the other hand, the price of Biogen Inc. (BIIB) has risen 1.44% today. The stock, however, is off 13.96% from where it was a year ago. Additionally, there is a gain of 0.46% for Johnson & Johnson (JNJ) in recent trading while the stock has seen an overall depriciation of 13.19%% over the past year. The PE ratio stands at 38.21 for AstraZeneca PLC, compared to 35.54 for Eli Lilly and Company, and 16.94 for Biogen Inc.. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it lost 0.00%. Meanwhile, the Dow Jones Industrial Slipped by -0.14%.
Data on historical trading for AstraZeneca PLC (NASDAQ:AZN) indicates that the trading volumes over the past 10 days have averaged 28.0 million and over the past 3 months, they’ve averaged 9.69 million. According to company’s latest data on outstanding shares, there are 2.62 billion shares outstanding.
Nearly 0.50% of AstraZeneca PLC’s shares belong to company insiders and institutional investors own 16.80% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 135.11 million shares as on Jun 14, 2021, resulting in a short ratio of 19.71. According to the data, the short interest in AstraZeneca PLC (AZN) stood at 5.15% of shares outstanding as of Jun 14, 2021; the number of short shares registered in May 13, 2021 reached 125.41 million. The stock has risen by 15.56% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AZN stock heading into the next quarter.